Literature DB >> 18485231

Calcific myofibrosis due to pentazocine abuse: a case report.

Vinay Goyal1, Jatinder M Chawla, Yatan Ps Balhara, Garima Shukla, Sumit Singh, Madhuri Behari.   

Abstract

INTRODUCTION: Pentazocine, a synthetic narcotic analgesic, is commonly used for the relief of moderate to severe pain secondary to various conditions. It is usually well tolerated; however, adverse effects are not uncommon, especially when higher doses are used and when it is used in a dependent fashion. There have been reports of various complications associated with its use, including skin fibrosis, skin ulceration, abnormal skin pigmentation and symmetrical myopathy with fibrous myopathy. Fibrosis has usually been reported in the muscles at the site of injection of the drug. Being opioid in nature, it has a high abuse potential. CASE
PRESENTATION: Here we report a case of pentazocine-induced calcific myofibrosis in a 42-year-old man involving muscles which were not injected with pentazocine.
CONCLUSION: This case highlights the care that needs to be taken when prescribing opioid analgesics, such as pentazocine, as routine painkillers. Patients who have history of substance abuse are more likely to abuse other agents, including prescription drugs. Rare consequences such as calcific myofibrosis are devastating and can cause significant lifelong disability.

Entities:  

Year:  2008        PMID: 18485231      PMCID: PMC2394532          DOI: 10.1186/1752-1947-2-160

Source DB:  PubMed          Journal:  J Med Case Rep        ISSN: 1752-1947


  9 in total

1.  Fibromyositis after intramuscular pentazocine abuse.

Authors:  M C Silva; P Singh; P Murthy
Journal:  J Postgrad Med       Date:  2002 Jul-Sep       Impact factor: 1.476

2.  Abduction contracture of the shoulders and hips secondary to fibrous bands.

Authors:  A J Wolbrink; Z Hsu; A J Bianco
Journal:  J Bone Joint Surg Am       Date:  1973-06       Impact factor: 5.284

3.  Cutaneous complications of parenterally administered pentazocine.

Authors:  J B Winfield; K Greer
Journal:  JAMA       Date:  1973-10-08       Impact factor: 56.272

4.  Pentazocine-induced myopathy.

Authors:  J C Steiner; A C Winkelman; P V De Jesus
Journal:  Arch Neurol       Date:  1973-06

5.  Hospitalized pentazocine abusers.

Authors:  D W Swanson; R L Weddige; R M Morse
Journal:  Mayo Clin Proc       Date:  1973-02       Impact factor: 7.616

6.  Local changes at the site of pentazocine injection.

Authors:  J E Schlicher; R L Zuehlke; P J Lynch
Journal:  Arch Dermatol       Date:  1971-07

7.  Intravenous pentazocine abuse by a nurse.

Authors:  R Hunter; I M Ingram
Journal:  Lancet       Date:  1983-07-23       Impact factor: 79.321

8.  Pentazocine-induced fibromyositis and contracture.

Authors:  C P Das; A Thussu; S Prabhakar; A K Banerjee
Journal:  Postgrad Med J       Date:  1999-06       Impact factor: 2.401

9.  Pentazocine-induced fibrous myopathy.

Authors:  S J Oh; J L Rollins; I Lewis
Journal:  JAMA       Date:  1975-01-20       Impact factor: 56.272

  9 in total
  3 in total

1.  Atypical myopathy: pentazocine induced.

Authors:  Murali K Kolikonda; Suneela Cherlopalle; Manasa Enja; Steven Lippmann
Journal:  Innov Clin Neurosci       Date:  2015 Mar-Apr

2.  Pentazocine abuse in a healthcare professional.

Authors:  Aslı Enez Darçın; Onur Cemal Noyan; Serdar Nurmedov; Nesrin Dilbaz
Journal:  BMJ Case Rep       Date:  2016-04-15

3.  Pentazocine-induced contractures: Dilemma in management.

Authors:  Dileep Kumar; Anil Gupta; V P Sharma; Ganesh Yadav; Arpita Singh; Ajay Kumar Verma
Journal:  Indian J Pharmacol       Date:  2015 Jul-Aug       Impact factor: 1.200

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.